Compare CSTM & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTM | PHVS |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | France | Switzerland |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2013 | 2021 |
| Metric | CSTM | PHVS |
|---|---|---|
| Price | $18.40 | $24.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $19.50 | ★ $39.44 |
| AVG Volume (30 Days) | ★ 1.1M | 559.8K |
| Earning Date | 10-29-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $7,969,000,000.00 | N/A |
| Revenue This Year | $9.43 | N/A |
| Revenue Next Year | $7.41 | N/A |
| P/E Ratio | $23.50 | ★ N/A |
| Revenue Growth | ★ 11.22 | N/A |
| 52 Week Low | $7.33 | $11.51 |
| 52 Week High | $18.75 | $29.80 |
| Indicator | CSTM | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 67.87 | 47.59 |
| Support Level | $17.20 | $23.15 |
| Resistance Level | $18.34 | $29.80 |
| Average True Range (ATR) | 0.65 | 2.06 |
| MACD | 0.18 | -0.37 |
| Stochastic Oscillator | 90.00 | 15.04 |
Constellium SE is engaged in the design and manufacture of rolled and extruded aluminium products, serving the packaging, aerospace, automotive, defence and other transportation and industry end-markets. The business is organized into three operating segments: the Packaging and Automotive Rolled Products segment which includes the production of rolled aluminium sheet products in European and North American facilities; the Aerospace and Transportation segment includes the production of rolled aluminium products and very limited volumes of extruded products in European and North American facilities; the Automotive Structures and Industry segment includes the production of extruded aluminium products and aluminium structural components.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.